Dr. Marty Makary is set to face intense scrutiny in his confirmation hearing for FDA commissioner, with key discussions expected about staff cutbacks and industry influences.

Novo Nordisk has reduced the price of Wegovy to $499 per month for patients without insurance coverage, aiming to improve accessibility after the end of the semaglutide shortage indicated by the FDA. The move mirrors similar initiatives by Eli Lilly. Experts suggest the price is still high, maintaining pressure on Novo Nordisk regarding drug affordability.

The F.D.A. has canceled a meeting of its vaccine advisory panel originally scheduled for March 13, raising concerns about potential delays in flu vaccine production.